EGFR Exon-Level Biomarkers of the Response to Bevacizumab/Erlotinib in Non-Small Cell Lung Cancer

Florent Baty(University of St.Gallen), Martin Brutsche(University of Basel), Cornelia Dröge(University Hospital of Basel), Sacha I. Rothschild(University Hospital of Basel), Daniel Rauch(Washington University in St. Louis), Miklos Pless(Ontario Institute for Cancer Research), Martin Früh(University of Bern), Richard Cathomas(Kantonsspital Graubünden), Francesco Zappa(Friedrich Schiller University Jena), Oliver Gautschi(Université Toulouse III - Paul Sabatier), Lukas Bubendorf(University of Basel), Susanne Crowe(Swiss Group For Clinical Cancer Research), Daniel Betticher
PLoS ONE
September 10, 2013
10.1371/journal.pone.0072966
Cited by 11

Related Papers

Tissue microarrays for high-throughput molecular profiling of tumor specimens
|Nature Medicine|1998|4.1k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.4k
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
|Journal of Clinical Oncology|2004|2.4k
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines
|European Urology|2020|2.2k
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
|The Lancet|2015|2k